Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Startseite
  2. Aktien
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. News
  7. Andere Sprachen
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Bericht
Verzögert Hong Kong Stock Exchange  -  09:08:41 30.01.2023
4.790 HKD   -2.44%
19.01.Sino Biopharmaceutical tilgt Anleihen in Höhe von 487,6 Millionen Euro
MT
13.01.China akzeptiert den Antrag von Sino Biopharmaceutical auf Vermarktung eines Lungenkrebsmedikaments
MT
13.01.Sino Biopharmaceutical Limited gibt den Antrag auf Vermarktung des innovativen Arzneimittels der Kategorie I, Tqb2450 Injektion in Kombination mit Anlotinib-Hydrochlorid-Kapseln, für die Erstbehandlung von kleinzelligem Lungenkrebs bekannt
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über SINO BIOPHARMACEUTICAL LIMITED
27.01.Hong Kong stocks ease ahead of China market reopening after Lunar New Year holiday
26.01.Hong Kong stocks hit 9-month high on lunar new year rush
19.01.Sino Biopharmaceutical to Redeem Bonds of 487.6 Million Euros
19.01.La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las..
16.01.Chinese Regulator Grants Marketing Approval to Akeso, Sino Biopharmaceutical's Lung Can..
13.01.China Accepts Sino Biopharmaceutical's Marketing Application for Lung Cancer Drug
13.01.Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innova..
11.01.Sino Biopharmaceutical Unit Gets Exclusive Commercialization Rights for Denosumab Injec..
03.01.Sino Biopharmaceutical Unit to Exclusively Market PL-5 Peptide
02.01.Sino Biopharmaceutical Gets Marketing Rights to COVID-19 Drug Ensitrelvir
2022Top Midday Gainers
2022F-Star Therapeutics Shares Erase Much of Thursday's Loss
2022F-star Therapeutics Extends invoX Deal Date to Help Address CFIUS Concerns; Shares Rise
2022Boan Biotechnology Raises HK$152.8 Million in Hong Kong IPO
2022Shandong Boan Biotechnology Seeks Up to HK$212 Million in Hong Kong IPO
2022Sino Biopharmaceutical Completes Patient Enrollment in Anti-Haemophilia Drug Trial
2022Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Cl..
2022Sector Update: Health Care Stocks Advance Modestly
2022Sino Biopharmaceutical's Q3 Revenue Rises 21%; Shares Rise 5%
2022Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
2022Sino Biopharmaceutical Limited Reports Unaudited Revenue Results for the Third Quarter ..
2022Sino Biopharmaceutical Limited Announces Resignation of Wang Shanchun as Executive Dire..
2022Trustee Purchases Sino Biopharmaceutical Shares for $1.3 Million
2022Trustee Purchases 2,780,000 Sino Biopharmaceutical Shares for $1.3 Million
2022Chinese Regulator Approves Clinical Trial of Sino Biopharmaceutical's COVID-19 Medicine..
2022Inventiva ADRs Rise 22% After Licensing Deal With Chia Tai-Tianqing Pharma
2022Chia Tai-Tianqing Signs Agreement for Lanifibranor
2022Sino Biopharmaceutical Trustee Purchases Shares for $1 Million
2022Sino Biopharmaceutical Trustee Purchases Additional $1 Million Shares
2022HanchorBio Inc. announced that it has received $10 million in funding from Zero2IPO Ven..
2022Sino Biopharmaceutical Limited announces an Equity Buyback for 1,882,009,423 shares, re..
2022China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
2022Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to ..
2022Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 ..
2022Sino Biopharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30..
2022Hong Kong Hang Seng Up 0.5% As Property and Tech Sectors Edge Higher
2022Sino Biopharmaceutical CEO Resigns
2022Sino Biopharmaceutical Limited Announces Resignation of Li Yi as Executive Director
2022Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
2022Generon Corporation Ltd. announced that it has received $70.000203 million in funding f..
2022Hong Kong Hang Seng Down 0.6% As Tech Issues Weaken
2022Sino Biopharmaceutical Submits Application for Marketing of Anti-Tumor Capsule
2022Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-T..
2022Sino Biopharmaceutical to Buy Nasdaq-listed F-Star Therapeutics for $161 Million; Share..
2022Sector Update: Health Care Stocks Lead Thursday Markets Recovery
2022Sector Update: Health Care Stocks Again Outpacing Other Sectors to the Ups..
2022Sector Update: Health Care
2022Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday
2022Sector Update: Health Care
2022F-star Therapeutics Shares Soar on Buyout Deal
2022Sino Biopharmaceutical Unit to Buy F-star Therapeutics for $161 Million
2022InvoX Pharma to Buy F-star Therapeutics in $161 Million Deal
2022Sino Biopharmaceutical Adjusts Conversion Price for Convertible Bonds
2022Sino Biopharmaceutical Obtains China Approval for Anti-Asthma Injectable Clinical Trial..
2022Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938..
2022SciClone Pharma Hires Former Sino Biopharma Exec as Chief Medical Officer; Shares Slide..
2022Hong Kong Hang Seng Down 0.6% As Tech Rally Stalls
2022Sino Biopharmaceutical Limited's Equity Buyback announced on July 27, 2021, has expired..
2022Generon Corporation Ltd. announced that it expects to receive $70 million in funding fr..
2022China Accepts Sino Biopharm's Marketing Application for Cancer Drug
2022Sino Biopharm Buys Back $278 Million of Euro-Denominated Bonds
2022Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor I..
2022Sino Biopharm Repurchases $168 Million of Euro-Denominated Bonds
2022Sino Biopharm Unit to Purchase Tumor Inhibitor of Danish Biotech Firm Symphogen
2022Hong Kong Stocks Rebound from Near Two-Month Low; Biotech Shares Rally
2022Sino Biopharm Repurchases $86.5 Million of Euro-Denominated Bonds
2022Sino Biopharmaceutical Signs License Deal for Hepatitis, Diabetes Drugs
2022Sino Biopharm Gets Clearance to Start China Clinical Trial of Anti-Tumor Drug
2022Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtain..
2022Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Appro..
2022Sino Biopharmaceutical's TQ-B3525 Drug Gets Breakthrough Therapy Drug Designation from ..
2022Chinese Drug Regulator Accepts Sino Biopharmaceutical's Respiratory Diseases Injection ..
2022Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the..
2022Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC293..
2022Sino Biopharm's New Product Launches Propel Profit by 427% in 2021
2022Sino Biopharm Unveils Share Buyback, Boosts Dividend as 2021 Profit Soars 427%
2022Hong Kong Hang Seng Index Up 0.2% in Late Rally
2022Sino Biopharmaceutical Limited Proposes Final Dividend for the Final Dividend for 2021,..
2022Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended Decembe..
2022Chinese Regulators OK Sino Biopharma's Clinical Trial of Solid Tumor Treatment
2022Sino Biopharm Wins Nod to Start China Clinical Trial of Solid Tumor Drug
2022Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHN..
2022Sino Biopharma Partners With Shenzhen XtalPi for Anti-Tumor Drug Development
2022Sino Biopharm's Drug for Overactive Bladder Wins Registration Approval in China; Shares..
2022Sino Biopharmaceutical Limited Announces Mirabegron Sustained-Release Tablets Obtained ..
2022Sino Biopharm Sees Up to Fivefold Increase in 2021 Profit; Shares Jump 7%
2022Sino Biopharm's Antibiotic Wins Marketing Approval, Generic Status in China; Shares Ris..
2022Sino Biopharmaceutical Limited Announces Linezolid Tablets Obtained Drug Registration C..
2022Sino Biopharmaceutical Limited Provides Group Earnings Guidance for the Year Ended 31 D..
2022US FDA OKs Sino Biopharma's Abbreviated NDA for Blood Lipid-Lowering Drug
2022Sino Biopharmaceutical Limited Announces Colesevelam Hydrochloride Tablets Obtained AND..
2022China Approves Market Launch of Sino Biopharm's Antipsychotic Medication
2022Sino Biopharmaceutical Limited's Lurasidone Hydrochloride Tablets Obtains Drug Registra..
2022Japanese Regulators Allow Sino Biopharma to Sell Anti-Rheumatic Drug
2022Sino Biopharma Arm Partners With Biocytogen Pharmaceuticals for Antibody Drugs Developm..
2022Chinese Regulators Grant Drug Registration Certificate to Sino Bio's Generic Rheumatoid..
2022Chinese Regulators Grant Drug Registration Certificates to Sino Bio's Generic Diabetes ..
2022Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate Tablet
2022Sino Biopharmaceutical Limited Obtains Drug Registration Certificate
2022Sino Biopharm Wins Greenlight to Start China Clinical Trial of Pneumoconiosis Treatment..
Anstehende Termine für SINO BIOPHARMACEUTICAL LIMITED